Verastem Inc (FRA:2VSA)
€ 4.06 0.24 (6.28%) Market Cap: 193.89 Mil Enterprise Value: 145.66 Mil PE Ratio: 0 PB Ratio: 16.62 GF Score: 35/100

Verastem Inc at Oppenheimer Healthcare Conference Transcript

Mar 19, 2019 / 03:30PM GMT
Release Date Price: €35.16 (+8.52%)
Unidentified Analyst

We are pleased to have Verastem with us today. Speaking on behalf of the Company we have Joe Lobacki, EVP and Chief Commercial Officer; Rob Gagnon, CFO; and Erin Cox, Investor Relations. Thank you so much.

Joe Lobacki
Verastem, Inc. - EVP and Chief Commercial Officer

Okay. Thank you very much, and thank you for having us here at the meeting. We are pleased to be here. So, again, I'm Joe Lobacki. I'll be presenting Verastem for you. Just some forward-looking statements. Again, we'll be -- I will be making forward-looking statements. Please make sure you refer to all of our SEC filings which you can find either through the SEC or on our website.

So with that, Verastem. So we are an oncology company focused in hematology right now. We are based out in Needham, just outside of Boston; so not too far outside of Boston, but up in that area. We incorporated in 2010. So the original focus was on stem cells; and one of those products we still have in our pipeline, defactinib. We will talk a little bit about that.

But the key product we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot